<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746979</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200592-001</org_study_id>
    <secondary_id>2012-002957-42</secondary_id>
    <nct_id>NCT01746979</nct_id>
  </id_info>
  <brief_title>Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma</brief_title>
  <acronym>MAESTRO</acronym>
  <official_title>A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Threshold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 trial is a randomized, double-blind, placebo-controlled trial of gemcitabine in
      combination with TH-302 compared to gemcitabine in combination with placebo in subjects with
      locally advanced unresectable or metastatic pancreatic adenocarcinoma. Randomized subjects
      will receive TH-302 plus gemcitabine or gemcitabine plus placebo in 4-week cycles until there
      is evidence of progressive disease, intolerable toxicity, or the subject discontinues from
      the trial for other reasons (for example, withdrawal of consent). The primary efficacy
      endpoint is overall survival (OS) time. The data cut-off for statistical analyses of the
      primary and secondary endpoints will be reached when 508 events (deaths) will be reported. No
      planned interim analyses will be conducted. An Independent Safety Monitoring Board (ISMB)
      will provide periodic evaluations of the unblinded safety data to ensure subject safety and
      the validity and scientific merit of the study. A total of 660 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Overall survival is defined as time from randomization to death or last day known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
    <description>Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">693</enrollment>
  <condition>Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine plus TH-302</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TH-302</intervention_name>
    <description>TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>Gemcitabine plus TH-302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>Gemcitabine plus TH-302</arm_group_label>
    <arm_group_label>Gemcitabine plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (5 percent dextrose - D5W)</intervention_name>
    <description>TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
    <arm_group_label>Gemcitabine plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma proven by
             histology or cytology and previously untreated with chemotherapy or systemic therapy
             other than:

               -  Radiosensitizing doses of 5-fluorouracil;

               -  Radiosensitizing doses of gemcitabine if relapse occurred at least 6 months after
                  completion of gemcitabine;

               -  Neoadjuvant chemotherapy if relapse occurred at least 6 months after surgical
                  resection;

               -  Adjuvant chemotherapy if relapse occurred at least 6 months after completion of
                  adjuvant chemotherapy

          -  Measurable disease (at least one target lesion outside of previous radiation fields)
             or non-measurable disease by RECIST v.1.1 criteria

          -  Documentation of disease progression since any prior therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Life expectancy of at least 3 month

          -  Acceptable liver, renal function and acceptable hematological status

          -  Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          -  New York Heart Association (NYHA) Class III or IV congestive heart failure, myocardial
             infarction within 6 months prior to the date of randomization, unstable arrhythmia or
             symptomatic peripheral arterial vascular disease

          -  Symptomatic ischemic heart disease

          -  Known brain, leptomeningeal or epidural metastases (unless treated and well controlled
             for at least 3 months)

          -  Previous malignancy other than pancreatic cancer in the last 5 years, except for
             adequately treated non-melanoma skin cancer or pre-invasive cancer of the cervix

          -  Severe chronic obstructive or other pulmonary disease with hypoxemia

          -  Major surgery, other than diagnostic surgery, less than or equal to 28 days prior to
             the date of randomization. Subject must have completely recovered from surgery

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy

          -  Treatment of pancreatic cancer with radiation therapy or surgery less than or equal to
             28 days prior to the date of randomization

          -  Prior therapy with a hypoxic cytotoxin

          -  Subjects who participated in an investigational drug or device trial less than or
             equal to 28 days prior to Day 1 of the first cycle

          -  Known infection with Human Immunodeficiency Virus (HIV), or an active infection with
             Hepatitis B or Hepatitis C

          -  Subjects who have exhibited allergic reactions to a structural compound similar to
             TH-302 or the drug product excipients or to gemcitabine or its excipients

          -  Other protocol defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Gualberto, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., a subsidiary of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please Contact U.S. Medical Information</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Please Contact Merck Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <results_first_submitted>July 18, 2017</results_first_submitted>
  <results_first_submitted_qc>October 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2017</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TH-302</keyword>
  <keyword>Evofosfamide</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>EMR200592-001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine Plus TH-302</title>
          <description>TH-302: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Gemcitabine Plus Placebo</title>
          <description>Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Placebo (5 percent dextrose - D5W): TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="346"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine Plus TH-302</title>
          <description>TH-302: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Gemcitabine Plus Placebo</title>
          <description>Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Placebo (5 percent dextrose - D5W): TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="346"/>
            <count group_id="B2" value="347"/>
            <count group_id="B3" value="693"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="9.70"/>
                    <measurement group_id="B2" value="63.8" spread="9.82"/>
                    <measurement group_id="B3" value="64.4" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="323"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as time from randomization to death or last day known to be alive.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine Plus TH-302</title>
            <description>TH-302: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine Plus Placebo</title>
            <description>Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Placebo (5 percent dextrose - D5W): TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as time from randomization to death or last day known to be alive.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.6" upper_limit="9.9"/>
                    <measurement group_id="O2" value="7.6" lower_limit="6.7" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine Plus TH-302</title>
            <description>TH-302: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Gemcitabine Plus Placebo</title>
            <description>Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Placebo (5 percent dextrose - D5W): TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression Free Survival is defined as the time from randomization to either first observation of progressive disease or occurrence of death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.8" upper_limit="5.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TH-302</title>
          <description>TH-302: TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Gemcitabine: Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Placebo (5 percent dextrose - D5W): TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="341"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="341"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="341"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="341"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="341"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infusion site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="341"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Stent malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholangiectasis acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholangiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="341"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatorenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enterococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infusion site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="341"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Prescribed overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Paraneoplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute interstitial pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="341"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin maceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Axillary vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="341"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="341"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="341"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="341"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="254" subjects_affected="108" subjects_at_risk="341"/>
                <counts group_id="E2" events="582" subjects_affected="164" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="29" subjects_at_risk="341"/>
                <counts group_id="E2" events="198" subjects_affected="47" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="248" subjects_affected="94" subjects_at_risk="341"/>
                <counts group_id="E2" events="546" subjects_affected="140" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="151" subjects_affected="61" subjects_at_risk="341"/>
                <counts group_id="E2" events="772" subjects_affected="158" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="149" subjects_affected="70" subjects_at_risk="341"/>
                <counts group_id="E2" events="110" subjects_affected="65" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="58" subjects_affected="38" subjects_at_risk="341"/>
                <counts group_id="E2" events="66" subjects_affected="44" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="146" subjects_affected="104" subjects_at_risk="341"/>
                <counts group_id="E2" events="171" subjects_affected="104" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="181" subjects_affected="89" subjects_at_risk="341"/>
                <counts group_id="E2" events="245" subjects_affected="112" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="320" subjects_affected="150" subjects_at_risk="341"/>
                <counts group_id="E2" events="354" subjects_affected="168" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="78" subjects_affected="53" subjects_at_risk="341"/>
                <counts group_id="E2" events="172" subjects_affected="86" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="233" subjects_affected="109" subjects_at_risk="341"/>
                <counts group_id="E2" events="243" subjects_affected="109" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="165" subjects_affected="71" subjects_at_risk="341"/>
                <counts group_id="E2" events="229" subjects_affected="81" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="219" subjects_affected="106" subjects_at_risk="341"/>
                <counts group_id="E2" events="234" subjects_affected="98" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="104" subjects_affected="72" subjects_at_risk="341"/>
                <counts group_id="E2" events="87" subjects_affected="64" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="147" subjects_affected="76" subjects_at_risk="341"/>
                <counts group_id="E2" events="104" subjects_affected="64" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="94" subjects_affected="29" subjects_at_risk="341"/>
                <counts group_id="E2" events="301" subjects_affected="52" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="122" subjects_affected="44" subjects_at_risk="341"/>
                <counts group_id="E2" events="476" subjects_affected="100" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="84" subjects_affected="28" subjects_at_risk="341"/>
                <counts group_id="E2" events="263" subjects_affected="55" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="184" subjects_affected="116" subjects_at_risk="341"/>
                <counts group_id="E2" events="205" subjects_affected="117" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="58" subjects_affected="45" subjects_at_risk="341"/>
                <counts group_id="E2" events="35" subjects_affected="30" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="341"/>
                <counts group_id="E2" events="57" subjects_affected="46" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="44" subjects_affected="27" subjects_at_risk="341"/>
                <counts group_id="E2" events="55" subjects_affected="44" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="341"/>
                <counts group_id="E2" events="81" subjects_affected="68" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="65" subjects_affected="46" subjects_at_risk="341"/>
                <counts group_id="E2" events="104" subjects_affected="63" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Wilson</name_or_title>
      <organization>Threshold Pharmaceuticals</organization>
      <phone>302-359-0565</phone>
      <email>twilson@thresholdpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

